NCT06287229View on ClinicalTrials.gov

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 11, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2030

Conditions
Relapsed/RefractoryB-cell Acute Lymphocytic Leukemia
Interventions
DRUG

Blinatumomab

Given by Infusion

DRUG

Inotuzumab Ozogamicin

Given by IV

DRUG

Hyper-CVAD

Given by IV Participants younger than 60 years of age, you will receive hyper-CVAD.

DRUG

Mini-hyper-CVD

Given by IV Participants 60 years of age or older, you will receive mini-hyper-CVD

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER